Cattle immunized against the pathogenic L-α-glycerol-3-phosphate oxidase of Mycoplasma mycoides subs. mycoides fail to generate neutralizing antibodies and succumb to disease on challenge by Mulongo, Musa M. et al.
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a  b  s  t  r  a  c  t
The  membrane-associated  enzyme  l--glycerol-3-phosphate  oxidase  (GlpO)  of  Mycoplasma  mycoides
subs. mycoides  (Mmm),  the  causal  agent  of  contagious  bovine  pleuropneumonia  (CBPP)  has  been  identiﬁed
as  a  virulence  factor  responsible  for the release  of toxic  by-products  such  as  H2O2 that  mediate  host  cell
injury.  Since  CBPP  pathogenesis  is based  on  host  inﬂammatory  reactions,  we  have  determined  the capacity
of recombinant  GlpO  to  generate  in  vivo  protective  responses  against  challenge  in immunized  cattle.  We
also  investigated  whether  sera  raised  against  recombinant  GlpO  in  cattle  and mice  inhibit  production  ofeywords:
ycoplasma
ntibody
accination
attle
H2O2 by Mmm.  Immunization  of  cattle  with  recombinant  GlpO  did  not  protect  against  challenge  with  a
virulent  strain  of Mmm.  Further,  although  both  murine  and  bovine  antisera  raised  against  recombinant
GlpO  detected  recombinant  and  native  forms  of  GlpO  in  immunoblot  assays  with  similar  titres,  only
murine  antibodies  could  neutralize  GlpO  enzymatic  function.  The  data  raise  the  possibility  that  Mmm
entiavolution
--glycerol-3-phosphate oxidase
has adapted  to  evade  pot
. Introduction
Mycoplasma mycoides subsp.  mycoides (Mmm)  is the causal agent
f contagious bovine pleuropneumonia (CBPP), a serious respira-
ory disease of cattle that causes major economic losses, especially
n sub-Saharan Africa [1,2]. In addition to tissue damage caused
y Mmm,  pathogenesis of CBPP arises partially from uncontrolled
nﬂammatory responses [3]. The most widely deployed vaccine
gainst CBPP is based on the live attenuated strain T1/44, which
nduces short-lived immunity and causes severe post-vaccinal
esions at the site of inoculation [4]. Mmm  belongs to the class
ollicutes, which comprises the smallest, and simplest of the
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free-living, self-replicating bacteria [5,6]. Because of their limited
genetic resources, Mollicutes are almost entirely dependent on host
biosynthetic activity and metabolism for survival and attach to host
cells for optimal growth [7].
Several authors demonstrated that Mmm translocates glycerol
from host interstitial ﬂuid through membrane-associated ATP-
binding cassette transporter proteins GtsA, GtsB and GtsC. Once
taken up, glycerol is phosphorylated to glycerol-3-phosphate (G3P)
and subsequently oxidized to dihydroxyacetone phosphate, with
the simultaneous release of H2O2 [8–10]. Pilo et al. identiﬁed
the trans-membrane l--glycerol-3-phosphate oxidase (GlpO) as
the enzyme responsible for oxidation of glycerol-3-phosphate
and generation of H2O2 and proposed that the metabolite and
other reactive oxygen species are translocated into the cytoplasm
of in-contact cells, resulting in cellular damage [9]. Importantly,
European strains of Mmm of the 1992–2000 epidemic, which pre-
dominantly caused chronic CBPP with less severe clinical signs, do
not possess the gtsB and gtsC genes and, consequently, release lower
amounts of H2O2 in the presence of physiological concentrations
of glycerol [10]. The pathogenicity of H2O2 arising from glycerol
metabolism by Mmm has been conﬁrmed in an in vitro model using
embryonic calf nasal epithelial (ECaNEp) cells [11]. Pretreatment of
Mmm with antibody binding fragments (Fab) derived from rabbit
reserved.
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olyclonal serum raised against rGlpO neutralizes enzyme activity,
s shown by inhibition of H2O2 release in the presence of glycerol
nd abrogation of the cytotoxic effect on ECaNEp cells [9].
The Mmm  vaccine strain T1/44 has an intact glycerol uptake and
etabolic system [11], and it is possible that H2O2 contributes to
ost-vaccinal reactions observed at the site of inoculation. In addi-
ion, H2O2 may  trigger the marked inﬂammation observed in the
ungs of Mmm  infected-cattle [9]. Therefore, a vaccine that targets
lpO and inhibits production of H2O2 by Mmm  would be desir-
ble, since it would be unlikely to elicit site reactions and would
rotect immune cattle undergoing infection from H2O2-associated
ytotoxicity. Such a vaccine could be produced in sub-unit form
sing rGlpO or the T1/44 strain could be genetically modiﬁed to
roduce a mutant devoid of the active enzyme, but retaining GlpO
pitopes capable of inducing antibodies with inhibitory capac-
ty. The latter approach was used to target the metabolic enzyme
ihydrolipoamide dehydrogenase of Mycoplasma gallisepticum and
ielded a vaccine with protection superior to that of three other
ommercial vaccines [12]. The potential of this approach in respect
f CBPP will depend on whether antibodies can be induced in cattle
hat bind GlpO and neutralize its activity, and whether such anti-
odies are protective. We  have therefore evaluated the capacity of
ovine and mouse GlpO antibodies to inhibit H2O2 release by Mmm
sing an in vitro assay of enzyme function. We  have also inves-
igated whether immunization of cattle with recombinant GlpO
onfers protection against challenge with live Mmm.
. Materials and methods
.1. Expression and puriﬁcation of recombinant GlpO
The poly-histidine tailed full length 45-kDa recombinant GlpO
rotein was expressed and puriﬁed from transformed E. coli BL21
DE3) harbouring glpO in the expression vector pETHIS-1 [13] and
repared as described by [9]. Brieﬂy, transformed E. coli were grown
nd puriﬁed by Ni2+ chelation chromatography as described for
ther recombinant proteins [14]. Fractions were analyzed by 12.5%
DS-PAGE using standard protocols and puriﬁed GlpO was dialysed
28,000 kDa cut-off) against PBS (pH 7.4) and quantiﬁed using the
oomassie (Bradford) Protein Assay Kit (Pierce, Rockford, IL, USA)
s described by the manufacturer.
.2. In vitro culture and quantiﬁcation of Mmm
Lyophilized aliquots of the virulent Mmm  isolate B237, which
riginated from an acute case of CBPP in central Kenya [15] were
econstituted in pre-warmed (37 ◦C) Gourlay’s medium [13] and
ropagated as described [16]. Mmm  for challenge infection was
uantiﬁed on the basis of colour changing units/ml (CCU/ml) using
he method of Spearman Karber [17] as described [16]. Mmm  was
onsidered suitable for inoculation on the third day of passage if
he culture appeared ﬁlamentous and was at pH 6.5.
.3. Cattle immunization and experimental infection
Cattle immunization was conducted following guidelines of the
.K. Animals (Scientiﬁc) Procedures Act, 1986 and was  approved by
he ethical review committees of the National Veterinary Research
entre, Muguga (Kenya) and the Moredun Research Institute (UK).
ourteen yearling Zebu steers from a CBPP-free zone of Kenya and
ero-negative by the CBPP complement ﬁxation test (CFT) were
andomly assigned into 2 groups each comprising 7 experimental
nimals and an equal number of controls. The experimental group
as inoculated sub-cutaneously with 200 g of rGlpO emulsiﬁed in
 ml  Complete Freund’s adjuvant (CFA). Cattle were boosted after
 weeks and again 6 weeks later with the same quantity of antigen 31 (2013) 5020– 5025 5021
emulsiﬁed in incomplete Freund’s adjuvant (IFA; Sigma). The con-
trol group was  similarly inoculated with CFA and boosted with IFA
emulsions in PBS respectively.
Challenge was  performed by endobronchial inoculation with
60 ml  of culture containing ∼108 CCU/ml of Mmm  after sedation
with 2 ml  of 2% Xylazine (Bayer AG, Leverkusen, Germany). The
inoculum was immediately followed by 30 ml of PBS and 15 ml
of pre-warmed 10% low melting agar. Clinical signs were moni-
tored daily and animals displaying continuous fever for ten days or
recumbancy for 3 days were euthanized on ethical grounds. Sur-
viving animals were euthanized at the end of the experiment on
day 35. All animals were bled for preparation of sera by jugular
venipuncture before challenge and prior to euthanasia.
2.4. Isolation of Mmm from experimental cattle
Lung tissue was immersed in 50 ml  pre-warmed Gourlay’s
medium containing phenol red indicator and incubated at 37 ◦C
in a humidiﬁed incubator with 5% CO2 for 3 days. Upon change of
colour to yellow, cultures were streaked on tryptose agar plates
(Difco), and incubated at 37 ◦C for 10 days. Four dilutions (1:10,
1:20, 1:30 and 1:40) of each broth culture were also prepared in
Gourlay’s medium. Mmm  isolation was considered positive if all
dilutions of broth cultures changed from orange colour to yellow
within 14 days and corresponding agar plates showed mycoplasmal
morphological features.
2.5. Mouse polyclonal and monoclonal antibodies
Polyclonal mono-speciﬁc serum against recombinant GlpO was
obtained by intra-peritoneal immunization of Balb/C mice with
50 g of puriﬁed rGlpO in 0.25 ml  of PBS, emulsiﬁed in an equal
volume of CFA, followed by two  booster immunizations with the
same quantity of antigen emulsiﬁed in IFA 2 and 6 weeks after
primary immunization. Three weeks after antigen was detectable
in immunoblots with serum dilutions of 1:1000 or more, mice
received a ﬁnal intravenous boost with 50 g of rGlpO in 250 l
PBS without adjuvant. Mice were euthanized three days later
and the spleens were harvested for production of monoclonal
antibodies, while blood was  collected by cardiac puncture for
preparation of polyclonal sera. Monoclonal antibodies were pre-
pared by fusion of splenocytes with X63.Ag8.653 myeloma cells
as previously described [14]. Supernatants from wells contain-
ing hybridoma colonies were screened for recognition of rGlpO
by immunoblot. Hybridomas harvested from positive wells were
cloned and the selection procedure repeated. A hybridoma lines,
designated MUG,1 was  obtained and further tested for speciﬁcity.
2.6. Immunoblot
Immunobloting was performed as described [18], with some
modiﬁcations. Brieﬂy, proteins were electro-blotted on nitrocel-
lulose (NC) membrane with pore size 0.45 m (Protran Whatman,
Gmbh Germany) under constant voltage of 20 V overnight at 4 ◦C.
Membranes were blocked in 5% BSA in PBS-T (PBS 0.05% Tween 20)
for 1 h then washed in PBS-T before being incubated for 1 h with the
relevant primary antibody diluted in PBS-T. After a further wash,
membranes were incubated for 1 h in horseradish peroxidase-
conjugated goat anti-bovine IgG or goat anti-mouse IgG (Sigma)
as appropriate. Bands were visualized by incubation in 30% DAB
and 1% H2O2 in PBS.2.7. Neutralization of enzyme activity by antibodies
The method of [10] was  used to measure the ability of anti-
GlpO sera to inhibit production of H2O2 by Mmm  strain B237
5 accine 31 (2013) 5020– 5025
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Fig. 1. (a) Coomassie staining showing the 47.5 kDa rGlpO after puriﬁcation by Ni2+
afﬁnity chromatography and resolution on 12.5% SDS-PAGE. M:  molecular weight.
(b) Immunoblot detection of recombinant and native GlpO by mouse GlpO anti-
serum; 5 g samples of puriﬁed rLppQ-N′ (lane 1) puriﬁed rGlpO (lane 2) and 10 g
samples of total Mmm lysate (lane 3) were subjected to 12.5% SDS-PAGE, transferred
to 0.45 m nitrocellulose membrane then probed with mouse GlpO anti-serum
(diluted at 1:1000). Rabbit anti-mouse IgG-HRP (diluted 1:4000) was used as the
secondary antibody. Note, the small difference in size between recombinant GlpO022 M.M. Mulongo et al. / V
n vitro. Thirty ml  of Mmm  culture in exponential growth phase
5 × 108 cells/ml) was centrifuged at 8000 × g for 15 min. The super-
atant was discarded and the pellet was washed by centrifugation
sing 10 ml  sterile pre-warmed (37 ◦C) incubation buffer (0.1 M
EPES, 1.4 M NaCl, 0.1 M NaOH and 7 mM MgCl2; pH 7.3). The
ulture was re-suspended in incubation buffer to a volume consis-
ent with an OD650 of 0.5–0.8 and 1 ml  aliquots were dispensed in
abelled 2 ml  centrifuge tubes. After addition of 200 l of diluted
nti-GlpO serum, tubes were incubated for 1 h in a 37 ◦C water
ath. Cells were then washed twice by centrifugation for 10 min
t 8000 × g at 37 ◦C, resuspended in 2 ml  incubation buffer contain-
ng glycerol at a ﬁnal concentration of 100 M and returned to the
7 ◦C water bath. Released H2O2 was quantiﬁed using Merckoquant
eroxidase test strips (Merck, Darmstadt, Germany). Starting 1 min
fter exposure to glycerol, a colorimetric strip was dipped in indi-
idual tubes for 1 s and the colour of the reaction zone was recorded.
n this way, released H2O2 was measured at intervals of 5, 10, 15,
0 and 40 min. The experiment was repeated on three occasions
nd mean of each treatment was determined.
.8. Bioinformatic analyses
Comparison of the GlpO protein sequence of Mmm (Gen-
ank accession number CAE46341) with the EMBL/GenBank
atabase was performed using the BLAST programme BLASTP
19]. Prediction of sub-cellular localizations was  made with
sortb v3.0.2 (http://www.psort.org/psortb/; [20]). Repartition of
etected proteins according to Cluster of Orthologous Group
as performed with COGnitor (http://www.ncbi.nlm.nih.gov/
OG/old/xognitor.html).
. Results
.1. Immunoblot
SDS-PAGE analysis of elutes from the Ni-NTA matrix revealed
he full-length 47 kDa rGlpO polypeptide along with additional
inor bands of various sizes (Fig. 1a). A 100 ml-culture of E. coli
ielded 2–4 mg  of protein, of which rGlpO was the principal molec-
lar component. Both mouse anti-GlpO serum (Fig. 1b) and serum
repared from GlpO-immunized cattle (Fig. 2b) reacted with native
mm GlpO at a dilution of 1:100, although serum from animal #670
howed a comparatively weak signal. As expected, sera from cattle
n the placebo group did not react with rGlpO (Fig. 2e). After chal-
enge, in addition to antibody responses to other Mmm proteins,
nimals in both groups showed strong responses to native GlpO at
 dilution of 1:100 (Fig 2c and d).
.2. In vitro neutralization of Mmm  H2O2 production by GlpO
ntisera
Release of H2O2 by untreated Mmm  after addition of glycerol
ncreased over 5–10 min  to reach a plateau of 2–5 g/ml, depending
n the experiment (Fig. 3). Signiﬁcant inhibition of peroxide release
as observed in Mmm  pretreated with varying dilutions of mouse
nti-serum raised against full length rGlpO (Fig. 3a) before addition
f glycerol, although inhibition was markedly reduced at a dilution
f 1:5000. Release of H2O2 was not observed in control preparations
onsisting of Mmm  and incubation buffer without glycerol.
Supernatant obtained from the MUG1 hybridoma (IgG2b) raised
gainst rGlpO was also tested for its ability to inhibit H2O2 release
y Mmm  (Fig. 3b). This supernatant signiﬁcantly blocked H2O2
elease at a dilution of 1:10, while partial blocking was apparent at
:100. However, the blocking capacity of this supernatant was  min-
mal at 1:1000, with released H2O2 reaching near baseline levels
fter 15 min  incubation. As expected, supernatants from mAb  PK2,(lane 2) and native GlpO as expressed by Mmm  (lane 3) is due to the additional
amino-terminal 10 histidine and carboxyterminal 6 histidine residues used for Ni2+
chelation chromatography standard.
which binds Mmm membrane polysaccharide [21] did not inhibit
H2O2 release.
Although seroconversion of cattle immunized with rGlpO was
conﬁrmed by immunoblot analysis, none of these sera inhibited
H2O2 production by Mmm,  before or after challenge infection
(Fig. 3c). Similarly, sera derived from non-immunized cattle after
challenge failed to inhibit H2O2 production by Mmm  (data not
shown).
3.3. Impact of GlpO immunization on the outcome of challenge
Clinical signs, antibody titres before euthanasia, survival, size
of lung lesions and mycoplasma isolation are shown in Table 1.
In both experimental and placebo groups, post-challenge clinical
signs were consistent with acute CBPP (3 vaccinates and 1 placebo)
and chronic CBPP (all remaining animals). Cattle displaying acute
CBPP and were euthanized before the end point. While 6 vacci-
nates and 4 placebo animals developed fever (≥39.5 ◦C) within
2 weeks after challenge, no signiﬁcant association was evident
between immunization status and the likelihood of developing
fever (Fisher’s exact test, p = 0.55). Four vaccinates displayed CBPP
lesions while only 1 placebo animal had a regressing lesion. Three
immunized and ﬁve placebo animals had single or multiple seques-
tra (Table 1).
3.4. Bioinformatic analysis
Bioinformatic analysis revealed no GlpO homologue in cattle.
The closest structurally related orthologue of GlpO of Mmm  in cat-
tle and other mammals is l-2-hydroxy glutarate dehydrogenase
(L2HDH; Acc. no. BC151577), an enzyme belonging to the FAD-
dependent superfamily of malate: quinone oxidoreductases of Bos
M.M. Mulongo et al. / Vaccine 31 (2013) 5020– 5025 5023
Fig. 2. Detection of native GlpO by antisera from GlpO-immunized cattle by immunoblot. 10 g samples of total Mmm  lysate were subjected to 12.5% SDS-PAGE, transferred
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To  0.45 m nitrocellulose membrane then probed with bovine GlpO anti-serum (d
re-challenge and post-challenge sera from GlpO immunized cattle, while those in 
ame  time-points. Goat anti-bovine IgG (H + L)-HRP (diluted 1:4000) was used as th
aurus and Bos grumiensis,  showing a maximum amino-acid (a.a.)
dentity of 26% over a coverage of 87% of the GlpO a.a. sequence,
−24ith an E-value of 2 × 10 . The only similarity between these
wo orthologues was found within the FAD binding site. Compar-
ng the a.a. sequence of the FAD binding site of Mmm GlpO with
he corresponding sequences of L2HDH of cattle (Bos taurus L2HDH
able 1
ummary of clinical, serological, pathological and bacteriological outcome of experiment
Animal ID Respiratory distress Fever S
(a) GlpO vaccinated group
652 Yes Yes 3
656  No Yes 3
658  Yes No 3
662  No Yes 1
664  No Yes 3
668  No Yes 2
670  No Yes 1
(b)  Placebo group
651 Yes No 3
654  No No 3
657  No Yes 3
659  No No 3
663  Yes Yes 2
667  Yes Yes 3
669  No Yes 3
he size shown is the longest dimensions (L × W)  of the area covered by the lesion s, sequ at 1:100); strips in panels (a)–(c) were respectively probed with pre-vaccination,
s (d), (e) and (f) were probed with sera from non-immunized cattle collected at the
ndary antibody.
GenBank accession no. BC151577), mouse (Mus  musculus L2HDH
GenBank accession no. AK152450) and rabbit (Oryctolagus cunicu-
lus L2HDH GenBank accession no. XM 002718232) reveals that the
bovine L2HDH FAD binding site is most closely related to FAD of
GlpO and to a lesser extent that of mouse, followed by that of rabbit
(Fig. 4).
al challenge in GlpO vaccinated and placebo groups.
urvival (days) Lung lesion (cm) Mmm  isolation
5 13 × 116.5 × 3 (s) +ve
5 9.3 × 8.5 (s) +ve
5 No −ve
5 10 × 19 12 × 12 +ve
5 10 × 7 (s)4 × 2 (s) +ve
0 15 × 22 +ve
5 26 × 15 +ve
5 12 × 11 (s) +ve
5 1.8 × 0.8 (ms) +ve
5 7.1 × 2 (s) +ve
5 No −ve
0 7 × 9 (rl) +ve
5 10 × 9 (s) +ve
5 4.8 × 4.3 (s) +ve
estrum; ms,  multiple sequestra; rl, lesion in recession.
5024 M.M. Mulongo et al. / Vaccine 31 (2013) 5020– 5025
Fig. 3. The capacity of anti-GlpO mouse polyclonal sera, MUG1 monoclonal antibodies and bovine sera to inhibit production of H2O2 by Mmm.  Mmm  were starved in PBS
at  37 ◦C and simultaneously pre-incubated with serum or hybridoma supernatants before addition of 100 M of glycerol and measurement of the quantity of H2O2 (y-axis)
by  Mmm  at the intervals shown (a) Mouse polyclonal sera against GlpO; −glyc neg control: Mmm that did not receive glycerol after starvation; +glyc: Mmm  that was not
incubated with serum but received glycerol after starvation; +glyc+serum: Mmm incubated with serum at the dilution shown and also received glycerol after starvation. (b)
Hybridoma supernatant containing anti-GlpO Mab: −glyc neg control: Mmm  that did not receive glycerol after starvation; +glyc: Mmm  that was not incubated with serum
but  received glycerol after starvation; +glyc+Pk2: Mmm  that was incubated with hybridoma supernatant containing antibodies against a the Mmm  capsular polysaccharide
(Pk2)  before addition of glycerol; +glyc+Mab: Mmm that was  incubated with hybridoma supernatant containing Mabs against GlpO at the dilutions shown before addition
of  glycerol. (c) Bovine sera against GlpO (dilution 1:1): −glyc neg control: Mmm that did not receive glycerol after starvation; +glyc: Mmm  that was  not incubated with
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. Discussion
We  have evaluated the capacity of a recombinant form of Mmm
lpO to protect cattle against challenge with the organism. Using
n immunization regimen based on Freund’s adjuvant formula-
ions, we found no evidence of protection in immunized animals,
espite evident sero-conversion. Indeed, vaccinates seem to show
ncreased pathological damage in comparison to challenge control
attle. This suggests either that GlpO is not a protective antigen, or
hat inappropriate immune responses were generated using Fre-
nd’s adjuvant. No information is currently available on the nature
f protective immunity in CBPP, although more favourable out-
omes have been associated with Mmm-speciﬁc IFN- secreting
D4+ T cells [22,23] and, independently, with speciﬁc serum IgA
ig. 4. Sequence comparison of the FAD binding sites of the GlpO-related oxi-
ases/dehydroxidases in Mmm,  cattle, mice and rabbit. GlpO Mmm: Glycerolphos-
hate oxidase of M. mycoides subsp. mycoides; L2HFH: l-2-hydroxyglutarate
ehydrogenase; L2HDH; l-2-hydroxyglutarate dehydrogenase. The comparison
ncluded in a ﬁrst step the entire FAD binding site with 3 ﬂanking a.a. The dif-
erences in the most conserved domain between GlpO Mmm  and bovine L2HDH
I–I–G–G–G–I) with the corresponding domain of mouse and rabbit L2HDH are
hown in colour.ubated with sera from vaccinated but uninfected cattle before addition of glycerol;
ra before addition of glycerol. For each data point, n = 7, and the error bars represent
responses [24]. We  did not collect data on these parameters in our
study.
With the exception of lung lesions in the immunized group
and sequestration in the placebo group, no clear differences were
apparent between the experimental and control groups with regard
to post-challenge clinical and pathological parameters. However,
immunized animals seemed to exhibit a more adverse outcome.
Three of these animals were euthanized on humane grounds before
the end of the experiment. Nonetheless, given the relatively low
number of animals involved, no deﬁnitive conclusion is possible
on whether immunization with recombinant GlpO results in a
more severe outcome of disease following experimental infection.
Enhanced pathology has been reported previously in cattle chal-
lenged with Mmm following immunization with a recombinant
form of the LppQ protein of the organism formulated in ISCOMs
[25]. The authors did not determine the underlying causes of the
enhanced pathology and, given that a different adjuvant system
was  used, it is difﬁcult to make direct comparisons between that
study and our observations.
Immunoblot analysis conﬁrmed that immunization with rGlpO
induced detectable antibody responses against the native GlpO
molecule, although these antibodies did not confer protection
in vivo. Anti-GlpO polyclonal mouse serum and a mAb  against rGlpO
inhibited H2O2 Mmm production. This is consistent with previ-
ous reports, which demonstrated that sera from GlpO-immunized
rabbits or mice could neutralize enzymatic activity of GlpO [9,26].
However, in our hands, sera from cattle immunized with rGlpO,
or from cattle infected with CBPP, failed to inhibit H2O2 produc-
tion by Mmm.  In addressing this dichotomy, we have identiﬁed a
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ingle amino-acid substitution in the ﬂavin-adenine-dinucleotide
FAD)-binding site (one of the main active sites of GlpO) of Mmm
lpO, as compared with the closest orthologue in cattle, mice
nd rabbits, L2HDH. It is tempting to speculate that adaptation
f Mmm  to mimic  neutralizing epitopes of bovine orthologues
s responsible for absence of neutralizing antibodies to GlpO of
mm  in cattle immunized with rGlpO. Such an eventuality might
rise from a requirement to avoid immune recognition of neu-
ralizing epitopes in cattle in order to retain enzyme function, in
ine with the importance of GlpO in its metabolism of glycerol
9].
In conclusion, our results indicate that induction of a humoral
esponse to rGlpO of Mmm  fails to protect cattle against challenge
ith the organism, with immunized animals showing apparently
nhanced pathology. The evident lack of GlpO neutralizing activity
n sera from immunized cattle when compared with that obtained
rom similarly immunized mice is intriguing, particularly in the
ight of a closer homology of GlpO with the bovine orthologue. Fur-
her work will be required to determine whether this truly reﬂects
n adaptation of the organism to avoid the generation of a neutral-
zing response against the enzyme in cattle.
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